Literature DB >> 8960879

Facilitation by substance P and inhibition by (+)-tubocurarine of the 5-HT3 receptor-mediated Bezold-Jarisch reflex in rats.

B Malinowska1, G Godlewski, W Buczko, M Göthert.   

Abstract

The influence of substance P 3 (microgram/kg) and (+)-tubocurarine (850 micrograms/kg) on the Bezold-Jarisch reflex in urethane-anaesthetized rats was studied. The Bezold-Jarisch reflex was induced by the 5-HT3 receptor agonist phenylbiguanide (0.3, 1, 3 and 10 micrograms/kg i.v.) and by capsaicin (10 micrograms/kg i.v.). The 5-HT3 receptor antagonist ondansetron (10 micrograms/kg) abolished the phenylbiguanide- but not the capsaicin-stimulated bradycardia, indicating that phenylbiguanide and capsaicin act via different trigger mechanisms (5-HT3 receptor-dependent and -independent, respectively). Substance P significantly potentiated the phenylbiguanide- but not the capsaicin-induced decrease in heart rate. Also, when the phenylbiguanide-induced response was amplified by substance P, it was abolished by ondansetron. (+)-Tubocurarine inhibited the phenylbiguanide-induced bradycardia, but did not affect the capsaicin-stimulated decrease in heart rate. Our results demonstrate that substance P potentiates but (+)-tubocurarine inhibits the 5-HT3 receptor-mediated Bezold-Jarisch reflex. Both effects are probably due to direct influences of the drugs on the 5-HT3 receptors on sensory vagal nerves in the heart.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960879     DOI: 10.1016/s0014-2999(96)00604-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex.

Authors:  Grzegorz Godlewski; Manfred Göthert; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 2.  Serotonin and beyond-a tribute to Manfred Göthert (1939-2019).

Authors:  H Bönisch; K B Fink; B Malinowska; G J Molderings; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-05-15       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.